News

10

Dec, 2020

Cascade of care in children and adolescents with HIV in the Russian Federation

Tags: , ,

The Cascade of Care, more commonly known as the HIV care continuum, is a calculation of how many people in a specific population diagnosed with HIV are initially linked to care, retained in care and have achieved viral suppression. It is an important tool in measuring success in controlling the HIV infection, identifying gaps in national HIV/AIDS strategies and set directions to improve care. On behalf of EPIICC and REACH researchers, Anna Turkova presented on the Cascade of Care of HIV positive children and adolescents in three Russian centres at […]

READ MORE

10

Dec, 2020

Cascade of care in children and adolescents with HIV in Russian Federation

Tags: ,

Author: Anna Turkova, Evgeny Voronin, Yulia Plotnikova, Anna Samarina, Edith Milanzi, Vladimir Rozenberg, Liubov Okhonskaia, Inga Latysheva, Aleksey Plynsky, Elena Fertikh, Siobhan Crichton, Charlotte Jackson, Ali Judd, Intira J Collins, on behalf of the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) Published in: 12th International Workshop on HIV Pediatrics View Poster   Background: The cascade of care summarises the 90-90-90 UNAIDS targets, of 90% of HIV+ people knowing their status, of whom 90% receive antiretroviral treatment (ART), of whom 90% are virally suppressed By 2019, there were 1,068,839 people […]

READ MORE

4

Dec, 2020

Pediatric dolutegravir (DTG) dosing recommendations derived from combined P1093 and ODYSSEY Population Pharmacokinetic analysis

Tags: ,

Authors: Singh R, Baker M, Thapar M, Gibb D, Turkova A, Ford D, Ruel T, Wiznia A, Farhad M, Alvero C, Green J, Bollen P, Colbers A, Burger D, Acosta E Published in: 12th International Workshop on HIV Pediatrics View Abstract booklet   Background: HIV treatment options remain limited in children. The recent Tivicay (dolutegravir, DTG) pediatric regulatory submissions propose WHO weight-band based recommendations for once-daily dosing in children ≥4 weeks of age using combined datasets from two pediatric studies: IMPAACT P1093 and ODYSSEY (PENTA20). These doses were informed by […]

READ MORE

26

Nov, 2020

Lindsey Hunter shares her one year living & working experience in Italy

 

I moved to Italy one year ago, after spending the entirety of my working life in London, United Kingdom. My move to Italy came about due to my Italian partner wanting to move back to Italy, after spending many years abroad. We decided to take the plunge – and here we are! I first heard of Penta in Italy from my work in the UK, and after seeing a job opening for a Communications Manager, I applied and started working at Penta in October 2019. Starting out in Penta Communications, I […]

READ MORE

19

Nov, 2020

European Medicines Agency approves use of Dolutegravir 5 mg dispersible tablet for younger children living with HIV

Tags: ,

On November 12th, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending marketing authorisation for dolutegravir 5mg dispersible tablets for young children living with HIV. This decision was based, in part, on data from the ODYSSEY trial. These small tablets can now be used in combination with other medicines for treating children living with HIV who are aged at least four weeks and weigh at least 3kg. CHMP’s positive opinion also supported the updated dosing recommendations for dolutegravir film-coated […]

READ MORE

19

Nov, 2020

#WorldAntimicrobialAwarenessWeek: Antimicrobial Stewardship Programs (ASPs)

Tags:

In the spirit of World Antimicrobial Awareness Week, we’d like to share a summary of the findings from the “Implementation and Impact of Paediatric Antimicrobial Stewardship Programs: A Systematic Scoping Review” study. As you may already know, Antimicrobial Stewardship Programs (ASPs) are a set of coordinated interventions designed to improve the selection of the appropriate agent, dose, route of administration, and therapy duration without compromising patient outcomes.

READ MORE
NEWSLETTER

We would like to update you on our recent activities